Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portola/Novartis Plan Phase III Trial For Elinogrel, With Eyes For Plavix Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Portola's anti-thrombotic vision: Execs discuss possibilities for two partnered, Phase III ready drugs - elinogrel and betrixaban.

You may also be interested in...



Portola's Heart Bypass Drug Gets Closed Advisory Committee Session

FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.

Portola's Heart Bypass Drug Gets Closed Advisory Committee Session

FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.

Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin

The attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting

Related Content

Topics

UsernamePublicRestriction

Register

PS071114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel